Navigation Links
CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
Date:11/26/2007

"small" HREF="http://studio.financialcontent.com/Engine?Account=prnewswire&PageName=QUOTE&Ticker=CRGN" onClick="var s=s_gi(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including the histone deacetylase inhibitor, belinostat, and the antibody-drug conjugate, CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

About TopoTarget

TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with subsidiaries in US, Switzerland, Germany and the UK, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FASligand and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule pre-clinical drug candidates and nine drugs (both small molecules and protein based) are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene(TM)/Totect(TM) was approved by EMEA in 2006 and the FDA in 2007 and is TopoTarget's first product on the market. For more information, please refer to http://www.topotarget.com.

Safe Harbor

Statements in this
'/>"/>

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... N.C. , Aug. 27, 2014 Kewaunee ... its Board of Directors increased its quarterly cash dividend ... eleven cents per outstanding share, beginning with the dividend ... at the close of business on September 8, 2014. ... Founded in 1906, Kewaunee Scientific Corporation is a ...
(Date:8/27/2014)... 2014 Amgen (NASDAQ: AMGN ) ... has granted priority review designation for ivabradine for the ... oral drug that inhibits the I f ... body,s cardiac pacemaker. 1 Ivabradine works to slow ... or ventricular repolarization. 1 Heart failure is a ...
(Date:8/27/2014)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), ... for its third quarter of fiscal 2014: For ... Revenue of $1,291,378, a 13% decrease over the same period ... quarter of $240,156 compared to net income of $238,826 during ... For the nine months ended June 30, 2014: ...
Breaking Medicine Technology:FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 2FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 3FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 4FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 5FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 6FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 7Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3
(Date:8/27/2014)... of hormone therapy has spawned a prevalent but preventable ... hot flashes, according to a study by a Yale ... the study published in the Aug. 27 online issue ... that moderate to severe hot flashes also called ... women. Women with VMS experience more than feeling hot; ...
(Date:8/27/2014)... (PDT, which uses topical agents and light to kill ... common skin lesion caused by sun damage) at three ... to freeze lesions). , Author: Gayatri Patel, ... Center, in Sacramento, and colleagues. , Background: ... found on individuals with fair complexions who have had ...
(Date:8/27/2014)... Michigan Head & Neck Institute is hosting a school ... school by ensuring they have everything they need for a ... Michigan Head & Neck Institute wants to ensure the children ... "There are a lot of military families in the area, ... back to our community," said Lauren Taylor, Marketing Coordinator at ...
(Date:8/27/2014)... Dr. Stewart Shofner and Dr. Kevin ... suffering from impaired vision. Some of the most common ... . Recently, Dr. Shofner has noticed a significant increase ... and also online. To help patients understand the facts, ... , 1)    Myth: People with perfect vision won’t develop glaucoma. ...
(Date:8/27/2014)... Washington, New York (PRWEB) August 27, 2014 ... dedicated to protecting the rights of victims injured by ... new rules in place for discovery procedures, specifically Collection ... brought over C.R. Bard’s transvaginal mesh devices. (MDL No. ... Products Liability Litigation, the United States District Court, Southern ...
Breaking Medicine News(10 mins):Health News:The high cost of hot flashes: Millions in lost wages preventable 2Health News:Photodynamic therapy vs. cryotherapy for actinic keratoses 2Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Debunks Top Five Myths About Glaucoma 4Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 2Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 3Health News:New Discovery Rules Have Been Put in Place by the Court Overseeing C.R. Bard Transvaginal Mesh Litigation, Parker Waichman LLP Comments 4
... Catalyst,Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today ... Third Quarter 2007 Results For the quarter ... of $734,347 or $0.06 loss per basic and diluted ... loss per basic and diluted share for the,same period ...
... Nov. 14 (HealthDay News) -- A protein that may have ... be a biomarker that indicates severe asthma. And it may ... to new research. , Reporting in the Nov. 15 issue ... University researchers said that people with severe asthma were more ...
... aim . . . , As the ... a high performance bullet based on technology developed at ... precision and superior terminal ballistics and is lead-free and ... Wakeman, Ohio, the technology is first being made available ...
... Reason for their added survival remains unclear, scientists say ... Hispanics appear to live longer following an Alzheimer,s diagnosis ... men and women of Asian and American Indian descent ... expectancies equivalent to that of white Alzheimer,s patients, ...
... December 31, RICHARDSON, Texas, Nov. 14 Blue ... will offer three Medicare Part D,prescription drug plans with ... Medicare beneficiaries in Texas can sign up,for or switch ... open enrollment period, which begins November 15 and continues ...
... Inc. announced today that CC Detect(SM), the ... now available from Panacea,Laboratories. CC Detect(SM) is ... identification of individuals with cancer of the ... standard screening methods. Panacea Laboratories,a division of ...
Cached Medicine News:Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 2Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 3Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 4Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 5Health News:Defensive Protein Linked to Asthma 2Health News:Defensive Protein Linked to Asthma 3Health News:Story tips from the Department of Energy's Oak Ridge National Laboratory, Nov. 2007 2Health News:Blacks, Hispanics Live Longer With Alzheimer's 2Health News:Blacks, Hispanics Live Longer With Alzheimer's 3Health News:Blacks, Hispanics Live Longer With Alzheimer's 4Health News:Blue Cross and Blue Shield of Texas Announces Flexible, Affordable Blue MedicareRx(SM) Medicare Prescription Drug Plans 2Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 2Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 3Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 4Health News:Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer 5
... Expandable, Multichannel Pipettor The Equalizer ... productivity with an industry breakthroughequal tip spacings ... a slide rod. This innovation allows the ... vessels with different configurations. Adjustable and ...
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
... Design for Unparalleled Comfort Pick one of ... balance. Notice the trigger and ejector positionsright where ... our pipettors are ergonomically designed to help avoid ... pipetting. Productivity In The Palm Of Your ...
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
Medicine Products: